Novo Nordisk’s Frehemgo (denecimig) was approved by the European Commission on 13 November 2026 as a once-monthly, every-two-weeks or once-weekly under-the-skin injection to prevent bleeding in adults and children with haemophilia A, with or without inhibitors. The approval follows a positive CHMP opinion in September and makes Frehemgo the second factor VIIIa-mimicking antibody in Europe after Roche’s Hemlibra. It is under FDA review and is already approved in Saudi Arabia.
Key takeaways on Frehemgo denecimig
- What it is: a bispecific antibody that bridges factors IXa and X, standing in for the missing factor VIII so the blood can clot.
- Who it is for: routine prophylaxis in adults and children with congenital haemophilia A, including the up to 30% of people with severe disease who develop inhibitors to factor VIII.
- Dosing: subcutaneous, from a single-use pre-filled pen, with a choice of monthly, fortnightly or weekly schedules.
- Evidence: the FRONTIER programme, led by FRONTIER2 in people aged 12 and over and FRONTIER3 in children under 12; Novo has not published numeric bleed rates in its approval release.
- India status: no Indian approval or CDSCO filing has been announced.
The approval in plain terms
People with haemophilia A lack working factor VIII, a protein that accelerates clotting. Traditional prophylaxis means intravenous factor infusions several times a week, which is hard on children’s veins and on families. Antibodies such as denecimig, also known during development as Mim8, mimic the job factor VIII does without needing to be infused into a vein. Because they are not factor VIII, inhibitors that neutralise replacement factor do not block them.
Novo says denecimig cut annualised bleeding rates significantly compared with previous factor prophylaxis and with on-demand treatment in FRONTIER2, that a substantial share of participants had no treated bleeds, and that results in children in FRONTIER3 were consistent. Thrombin generation rose into the normal range and stayed there without reaching levels suggesting excess clotting risk. The company has not given exact bleed-rate figures in the approval announcement, so the size of the benefit should be checked against the published trial papers and the EU product information.
The FRONTIER trials behind Frehemgo
| Trial | Population | What it tested |
|---|---|---|
| FRONTIER2 (pivotal) | Adults and adolescents 12+ | Monthly and weekly dosing vs prior factor prophylaxis and on-demand care |
| FRONTIER3 | Children under 12 | Monthly and weekly dosing |
| FRONTIER4 | Open-label extension | Every-two-weeks dosing, long-term safety across all regimens |
| FRONTIER5 | People on emicizumab | Direct switch, safety and device preference |
Frehemgo vs Hemlibra: where the difference lies
Hemlibra (emicizumab) already offers weekly, two-weekly and four-weekly dosing, so monthly convenience alone is not new. Novo is betting on three points: a pre-filled pen rather than vials and syringes, higher potency that Novo says brings thrombin generation closer to normal, and FRONTIER5, which showed patients could switch straight from emicizumab without new safety signals. Head-to-head bleed data versus Hemlibra do not exist, so any claim of superiority would be premature. For many families, price, pen handling and payer coverage are likely to decide which antibody they use.
What it could mean for patients in India
India is widely reported to have one of the world’s largest haemophilia populations, much of it undiagnosed, and many patients still depend on on-demand factor supplied through state programmes. Novel non-factor therapies are starting to arrive: we recently covered Sanofi’s Qfitlia approval in India. Frehemgo has no Indian approval yet, and Novo has not announced plans for the market. Patients should not seek to import it and should discuss prophylaxis options with a haemophilia treatment centre.
Haemophilia market context
Acumen Research and Consulting valued the global hemophilia market at USD 12.2 billion in 2021 and projected it to reach USD 21.9 billion by 2030, a CAGR of 6.9%. Haemophilia A accounted for more than 82% of market share, North America held over 44%, and Asia-Pacific was expected to grow fastest. The report was last updated in November 2022, so these numbers are dated and indicative, but they show why Novo sees haemophilia A as the prize segment to challenge Roche.
Next milestones
- The FDA decision on denecimig in the US; Novo has not disclosed a target date.
- Country-by-country EU launches and reimbursement decisions.
- Publication of full FRONTIER2 and FRONTIER3 bleed-rate data in the EU product information.
People also ask
What is Frehemgo used for?
Frehemgo (denecimig) is used as routine prophylaxis to prevent or reduce bleeding episodes in adults and children with haemophilia A, with or without factor VIII inhibitors.
How often is denecimig injected?
The EU approval allows once-monthly, once-every-two-weeks or once-weekly subcutaneous injections using a pre-filled pen. Dosing should be set by the treating haematologist.
Is Frehemgo approved by the FDA?
Not yet. It is under FDA review. It is approved in the EU and Saudi Arabia.
Is Frehemgo available in India?
No. There is no Indian approval and no announced filing as of 14 November 2026.
More from our Drug Approvals section.
Sources: Novo Nordisk release (13 Nov 2026); Reuters. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 14 November 2026.

[…] that determine real access across EU countries. For other recent EU decisions, see our coverage of Frehemgo’s EU approval and the Gazyva lupus CHMP opinion, or browse all drug […]
[…] patients onto the weekly product. For broader context on Novo’s pipeline, see our coverage of Novo’s monthly haemophilia A shot and our FDA approvals […]